A Study of ONO-1110 in Patients With Postherpetic Neuralgia
NCT ID: NCT06708416
Last Updated: 2025-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
140 participants
INTERVENTIONAL
2025-02-12
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia
NCT01058642
RN624 For Pain Of Post-Herpetic Neuralgia
NCT00568321
A Comparative Study of KHK6188
NCT01544296
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
NCT01129531
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
NCT00115310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ONO-1110
ONO-1110 tablets once a day
ONO-1110
ONO-1110 tablets once a day
Placebo
Placebo tablets once daily
Placebo
Placebo tablets once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONO-1110
ONO-1110 tablets once a day
Placebo
Placebo tablets once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age (at the time of informed consent): 18 years and older
* Outpatient
* Patients with persistent pain ≥3 months (90 days) after the onset of herpes zoster
* Patients who are considered capable of understanding the study procedures and completing the pain diary and questionnaires appropriately by the investigator (sub-investigator)
Exclusion Criteria
* Patients with pain other than PHN that may affect assessments in this study
* Patients with any skin condition related to the site of herpes zoster that may affect assessments in this study
* Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
* Patients with concurrent psychiatric diseases that may affect assessments in this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Project Leader
Role: STUDY_DIRECTOR
Ono Pharmaceutical Co. Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kamezawa Clinic
Aichi, , Japan
Kimura Clinic
Aichi, , Japan
Fukuoka Tokushukai Hospital
Fukuoka, , Japan
Southern Tohoku General Hospital
Fukushima, , Japan
Central Japan International Medical Center
Gifu, , Japan
National Hospital Organization Kure Medical Center
Hiroshima, , Japan
National Hospital Organization Hokkaido Medical Center
Hokkaido, , Japan
Nishinomiya Municipal Central Hospital
Hyōgo, , Japan
Mito Saiseikai General Hospital
Ibaraki, , Japan
Kawasaki Municipal Hospital
Kanagawa, , Japan
Konan Hidamari Pain Clinic
Kanagawa, , Japan
Tai Clinic
Kanagawa, , Japan
Yokohama City Minato Red Cross Hospital
Kanagawa, , Japan
Junwakai Memorial Hospital
Miyazaki, , Japan
Medical Corporation Toyama Dermatology
Miyazaki, , Japan
Yuaikai Tomishiro Chuo Hospital
Okinawa, , Japan
Morimoto Clinic
Osaka, , Japan
Osaka Metropolitan University Hospital
Osaka, , Japan
Medical Corporation Fujigaki Clinic
Ōita, , Japan
Shizuoka Rehabili Pain Clinic
Shizuoka, , Japan
Fukuuchi Pain Clinic
Tokyo, , Japan
Fukuwa Clinic
Tokyo, , Japan
Futaki Skin Care Clinic
Tokyo, , Japan
Juntendo University Hospital
Tokyo, , Japan
Mitaka Pain Clinic
Tokyo, , Japan
Nishiogi Pain Clinic
Tokyo, , Japan
Tokyo-Eki Center-Building Clinic
Tokyo, , Japan
Yamanashi Prefectural Central Hospital
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
jRCT2031240504
Identifier Type: REGISTRY
Identifier Source: secondary_id
ONO-1110-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.